Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Rationale: Dominant heterozygous variants in Filamin C (FLNC) cause diverse cardiomyopathies, though the underlying molecular mechanisms remain poorly understood. Objective: We aimed to define the molecular mechanisms by which FLNC variants altered human cardiomyocyte gene and protein expression, sarcomere structure, and contractile performance. Methods and Results: Using CRISPR/Cas9, we introduced FLNC variants into human cardiomyocytes derived from induced pluripotent stem cells (hiPSC-CMs). We compared isogenic hiPSC-CMs with normal (WT), ablated expression ( FLNC -/- ) or haploinsufficiency ( FLNC +/- ) that causes DCM. We also studied a heterozygous in-frame deletion ( FLNC +/∆7aa ) which did not affect FLNC expression but caused aggregate formation, similar to FLNC variants associated with hypertrophic cardiomyopathy (HCM). FLNC -/- hiPSC-CMs demonstrated profound sarcomere misassembly and reduced contractility. While sarcomere formation and function were unaffected in FLNC +/- and FLNC +/∆7aa hiPSC-CMs, these heterozygous variants caused increases in lysosome content, enhancement of autophagic flux, and accumulation of FLNC-binding partners and Z-disc proteins. Conclusions: FLNC expression is required for sarcomere organization and physiologic function. Variants that produce misfolded FLNC proteins cause the accumulation of FLNC and FLNC binding partners which leads to increased lysosome expression and activation of autophagic pathways. Surprisingly, similar pathways were activated in FLNC haploinsufficient hiPSC-CMs, likely initiated by the loss of stoichiometric FLNC protein interactions and impaired turnover of proteins at the Z-disc. These results indicate that both FLNC haploinsufficient variants and variants that produce misfolded FLNC protein cause disease by similar proteotoxic mechanisms, and indicate the therapeutic potential for augmenting protein degradative pathways to treat a wide range of FLNC-related cardiomyopathies.

Original publication

DOI

10.1161/circresaha.120.317076

Type

Journal article

Journal

Circulation Research

Publisher

Ovid Technologies (Wolters Kluwer Health)

Publication Date

18/08/2021